Discontinuation report GD-GABAPENTIN
| Report ID | 67262 |
| Drug Identification Number | 02285843 |
| Brand name | GD-GABAPENTIN |
| Common or Proper name | GD-GABAPENTIN |
| Company Name | GENMED A DIVISION OF PFIZER CANADA ULC |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | GABAPENTIN |
| Strength(s) | 600MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL |
| Packaging size | 100's |
| ATC code | N03AX |
| ATC description | ANTIEPILEPTICS |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | 2019-09-30 |
| Actual discontinuation date | 2019-09-26 |
| Remaining supply date | 2019-09-26 |
| Discontinuation status | Discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 17300 TRANS CANADA HIGHWAY KIRKLAND, QUEBEC CANADA H9J 2M5 |
| Company contact information | Customer Service / service à la clientèle : 1-800-387-4974 Email / courriel: PharmaCustomerServiceDept@pfizer.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v1 | 2018-11-20 | English | Compare |
| v2 | 2018-11-20 | French | Compare |
| v3 | 2019-09-26 | English | Compare |
| v4 | 2019-09-26 | French | Compare |
Showing 1 to 4 of 4